profit from every $100 of sales.
$0$100
Neuphoria Therapeutics
$2.71+0.74% today
-44.6% in 1 year
1-year low $2.691-year high $5.48
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Neuphoria Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2021 to $0 in 2024, with -$15.5 million of profit last year.
SalesProfit
Neuphoria Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Neuphoria Therapeutics | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads Neuphoria Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -9 | -15 | -22 | -18 | |
| -5 | -14 | -21 | -17 | |
| -7 | -15 | -21 | -15 | |
| – | -0.17 | -0.16 | -0.12 | |
| – | – | – | – | |
| – | -8,095.1% | – | – | |
| – | -8,253.6% | – | – |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 41 | 45 | 29 | 28 |
| Cash | 21 | 23 | 12 | 13 |
| Total debt | 1 | 0 | 0 | 0 |
| Total liabilities | 5 | 6 | 7 | 10 |
| 36 | 39 | 22 | 17 | |
| – | 1,353 | 122 | 150 | |
| -12.6% | -30.1% | -76.0% | -79.2% | |
| -18.3% | -38.2% | -97.1% | -88.6% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| -6 | -15 | -15 | -15 | |
| 0 | 0 | – | – | |
| -6 | -15 | -15 | -15 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 1 | 2 | 1 | 1 |
Valuation
- –
- –
- –
- 0.8×
- 80.9×
- –
- –
- -102.1%
- -102.1%
- 0.0%
Profitability
- 95.7%
- -8,095.1%
- -8,253.6%
- -10,304.9%
- -1,466.4%
- -71.9%
- -1,538.3%
- -1,020.1%
- -3,310.9%
- 109,708.9%
Growth
- –
- –
- +626.0%
- –
- −60.2%
Financial health
- -1.6×
- 0.00
- 0.1%
- –
- 9.04
- 9.04
- 0.22
What analysts expect
- Average price target
- $7.00
- Range
- $7.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.09 | -0.56 | +83.9% |
| Feb 17, 2026 | -0.77 | -0.56 | −37.5% |
| Nov 14, 2025 | -4.41 | -0.55 | −701.8% |
| Sep 29, 2025 | -5.79 | -0.56 | −933.9% |
| May 20, 2025 | 6.55 | -0.47 | +1,493.6% |
| Mar 17, 2025 | -0.01 | -2.01 | +99.6% |
| Nov 15, 2024 | -0.00 | – | – |
| Sep 30, 2024 | -29.16 | -11.38 | −156.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/5Passes 2 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
77Pass
Philip Fisher
–Not enough data
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
60Pass
Terry Smith
54No pass
Questions about Neuphoria Therapeutics
Is Neuphoria Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Neuphoria Therapeutics AI analysis
What does Neuphoria Therapeutics do?
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. It is in Medical - Pharmaceuticals.
Does Neuphoria Therapeutics pay a dividend?
No. Neuphoria Therapeutics does not pay a dividend at the moment.
Is Neuphoria Therapeutics stock halal?
No. Neuphoria Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 86% of its market value, at or above the 33% limit. How we check
How has Neuphoria Therapeutics stock done over the past year?
Down 44.6% over the past twelve months, to $2.71. It traded between $2.69 and $5.48 and is 50.5% below its high.
Who are Neuphoria Therapeutics's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with Neuphoria Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.